

Larry R. Zobel, MD, MPH
Staff Vice President
and Medical Director

3M Medical Department

3M Center, Building 220-2E-02
PO Box 33220
St. Paul, MN 55133-3220
651 733 5181 Office
651 733 5152 Facsimile

35326

FYI-0500-1378

AR226-0001

April 25, 2000

3M

Dr. Oscar Hernandez
US EPA/OPPT/CCD (7405)
401 M Street, SW
Room E615B
Washington, DC 20460

VIA FEDERAL EXPRESS

Dear Dr. Hernandez:

(ATTACHMENTS PROVIDED TO TSCA
DOCUMENT PROCESSING CENTER WITH
8E HQ-0400-00373)

Enclosed are copies of the following documents which were inadvertently omitted from our package sent to you last Friday, April 21, 2000:

1. Protocol 418-008 Combined oral (gavage) fertility, developmental and perinatal/postnatal reproduction toxicity study of PFOS in rats (Sponsor's study number: 6295.9), Table E20, 1-3;
2. Harb, R.V., Hartman, H.A. and Cox, R.H. (1994), Prevention of fluvastatin induced toxicity, mortality, and cardiac myopathy in pregnant rates by mevalonic acid supplementation. *Teratology*, **50**, 19-26;
3. Haugom, B. and Spydevold, O. (1992), The mechanism underlying the hyperlipemic effect of perfluorooctanoic acid (PFOA), perfluorooctate sulphonic acid (PFOS) and clofibrilic acid. *Biochimica et Biophysica Acta*, **1128**, 65-72;
4. Levin, M.S. Pitt, A.J.A., Schwartz, A.L., Edwards, P.A. and Gordon, J.I. (1989), Developmental changes in the expression of genes involved in cholesterol biosynthesis and lipid transport in human and rat fetal and neonatal livers. *Biochimica et Biophysica Acta*, **1003**, 293-300; and
5. Interoffice memo from Tom Kestner to Leo Gehlhoff, "Fluorochemical Isomer Distribution by ¹⁹F-NMR Spectroscopy," December 1, 1997.

If you have any questions or need additional information, please feel free to contact me at 651-733-5181.

Sincerely,

L. R. Zobel MD

Larry R. Zobel, MD MPH
Staff Vice President & Medical Director

LRZ:kmj
Enclosures

Contain NO CBI



84000000018



000001

FYI-00-001378

RECEIVED
OPPT/CCD
MAY - 2 11 14 00